Marco Gerlinger

Medical Oncologist and Clinician Scientist working on GI Cancer Genomics/Cancer Evolution, Immunotherapies and Biomarkers

[St Bartholomew's Hospital GI Cancer Centre @BartsGI_Cancer]

Delighted to host our collaborators @DrHongchengZhu and Dr Xia from Fudan University Hospital at @BartsGI_Cancer this week. Working with Prof @MarcoGerlinger, and Drs @LucyKFlanders, Lerner & Nenclares to improved organ preservation strategies in rectal cancer: 40-50% is in reach

[Marco Gerlinger @MarcoGerlinger]

🔥Just opened: 4 year CLINICAL LECTURERSHIP position in HISTOPATHOLOGY @NHSBartsHealth and my lab @QMBCI in London: for ST3/4 registrars who already hold a PhD/MD. Great opportunity for a deep dive into the immunobiology of MMRd cancer. Deadline 11/04 10am https://t.co/MDV9s1DBSB

[Marco Gerlinger @MarcoGerlinger]

Still time to register for our free @AACR IO webinar today: “Tumour Mutation Burden, Heterogeneity and Immunotherapy Efficacy”with Profs Jaffe, Quezada and Wargo https://t.co/eni5HZNryY

[Marco Gerlinger @MarcoGerlinger]

Join the discussion: Pervasive Cellular Plasticity intertwined with Darwinian Evolution in Cancer - does this need a new Evolutionary Theory? See our review just out in @trendscancer https://t.co/6lxH96UxzV

[Marco Gerlinger @MarcoGerlinger]

Touched down in Miami for the 2024 @CCAlliance #CureCRC Summit - very exciting to be here again to help make this cancer history. Well prepared after lovely Christmas dinner and afternoon tea (‼️‼️) on board of the A380 💪💪💪

[Hongcheng Zhu 祝鸿程 @DrHongchengZhu]

Starting from International Exchange Award between UK and China supported by @royalsociety, more exciting opportunities have been discussed for collaboration in clinical and translational research between the two premier centers in London and Shanghai 🇬🇧🇨🇳

[St Bartholomew's Hospital GI Cancer Centre @BartsGI_Cancer]

Kickoff meeting of our new St Barts Hospital - Fudan University Cancer Centre Oesophageal Cancer Research Collaboration in Shanghai today and yesterday. Very grateful to @RoyalSociary for funding this project which is led by Prof @MarcoGerlinger and Prof Zhen Zhang

[Marco Gerlinger @MarcoGerlinger]

Outstanding session with @elena_elez and @BenjcRousseau on immunotherapy biomarkers at @ASCO #ASCO24 this morning. Key messages: Exciting and powerful new IO biomarkers on the horizon. We now need to apply them to large clinical trials including those from industry.

[Marco Gerlinger @MarcoGerlinger]

Great talk on chromosomal instability by my @QMBCI colleague Dr McClelland @McclellandLab at #AACR24 @AACR in RM29 ongoing

[Yale Cancer Center @YaleCancer]

.@politikaterina will be presenting during the Lineage Plasticity in Tumor Evolution and Acquired Resistance educational session at #AACR24, this morning at 8am PST/11am EST.
https://t.co/XKaP12kwLB
@SmilowCancer @YaleMed @YNHH @yalepathology @YaleThoracic

[Charles Swanton @CharlesSwanton]

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24, out in @CD_AACR today https://t.co/5bWeXqK2I0 Tweetorial👇

[Yale Cancer Center @YaleCancer]

.@JeffTownsend discussed how the evolution of #cancer is rarely linear, but a branching model that influences progression #AACR24 “Every one of our bodies has a tree of history underlying every cell in our body.” #phylogenetics @AACR @SmilowCancer @YaleMed @YaleSPH

[Marco Gerlinger @MarcoGerlinger]

Looking forward to meet for a drink (and science discussion of course…)

[Marco Gerlinger @MarcoGerlinger]

Important POSTER SESSIONS For those of you at #AACR24:
👉🏻Tumor Evolution in Space and Time is on Monday 9am-12:30 (section 12)
👉🏻Tumor Evolution Models and Technologies on Tuesday 9am-12:30 (section 13)
We received 🏅outstanding 🥇 abstracts this year. Don‘t miss out!!

[Myriam Chalabi @MyriamChalabi]

What a great start of 2024! Excited, happy and proud to share our latest work published today #openaccess @NatureMedicine on the PANDA trial: neoadjuvant atezo+chemo in pts with gastric/GEJ cancers followed by surgery. Some of the key findings below. 1/10 https://t.co/ApfPdsYu2f

[Barts Cancer Institute (Queen Mary) @QMBCI]

We're delighted that Prof Tom Powles (@tompowles1) has been selected as one of @Nature's 10 people who shaped science for his transformative clinical work delivering a life-extending treatment for severe bladder cancer.

A huge honour – congratulations to Tom and his team 👏👏👏

[Marco Gerlinger @MarcoGerlinger]

It’s a great honour to be part of the @CCAlliance inaugural #CureCRCsummit this week. Brainstorming strategies to cure #colorectal cancer with giants in the field Drs @skopetz, Batlle, Venook, Lenz, @MyriamChalabi, @AndreaCercek + many others

[St Bartholomew's Hospital GI Cancer Centre @BartsGI_Cancer]

Important point made in an article in @guardian today: better outcomes for cancer patients who are treated in research active hospitals

[Marco Gerlinger @MarcoGerlinger]

-Parallel evolution which surpasses even that in RCC!
-Big headache for biomarker development!
Our study on ITH in dMMR CRCs is out: https://t.co/TMl731SW7f
High mutation supply and strong immune selection pressures make this a great model tumor for #CancerEvo studies

[Marco Gerlinger @MarcoGerlinger]

@BartsGI_Cancer @tompowles1 An absolutely amazing result that transforms bladder cancer management. Congratulations Tom!